ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
US Tech 100
18,066.00
-0.07%
Dow Jones
40,003.59
0.34%
Brent Oil
83.76
0.00%
Bitcoin
66,867.54
-0.32%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Abliva Ab (0QDU)

  7. Abliva Ab (0QDU) News

0QDU

Abliva Ab (0QDU)

Abliva Ab
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0QDU
DateTimeSourceHeadlineSymbolCompany
02/19/20203:03AMPR Newswire (US)NeuroVive Pharmaceutical AB Year End Report January - December 2019LSE:0QDUAbliva Ab
02/19/20203:01AMPR Newswire (US)NeuroVive Pharmaceutical AB Year End Report January - December 2019LSE:0QDUAbliva Ab
12/20/20199:44AMPR Newswire (US)NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b StudyLSE:0QDUAbliva Ab
12/20/20199:40AMPR Newswire (US)NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b StudyLSE:0QDUAbliva Ab
12/16/20195:21AMPR Newswire (US)NeuroVive Announces Settlement in Dispute With CicloMulsion AGLSE:0QDUAbliva Ab
12/16/20195:19AMPR Newswire (US)NeuroVive Announces Settlement in Dispute With CicloMulsion AGLSE:0QDUAbliva Ab
11/20/20193:04AMPR Newswire (US)NeuroVive Pharmaceutical AB Interim Report January - September 2019LSE:0QDUAbliva Ab
11/20/20192:58AMPR Newswire (US)NeuroVive Pharmaceutical AB Interim Report January - September 2019LSE:0QDUAbliva Ab
08/21/20192:55AMPR Newswire (US)NeuroVive Pharmaceutical AB Interim Report January - June 2019LSE:0QDUAbliva Ab
08/21/20192:52AMPR Newswire (US)NeuroVive Pharmaceutical AB Interim Report January - June 2019LSE:0QDUAbliva Ab
08/20/20197:23AMPR Newswire (US)Save the Date: NeuroVive to host Capital Markets Day in Stockholm on 9 October, 2019LSE:0QDUAbliva Ab
07/27/20197:38AMPR Newswire (US)NeuroVive's NeuroSTAT Project Receives FDA Fast Track DesignationLSE:0QDUAbliva Ab
07/27/20197:35AMPR Newswire (US)NeuroVive's NeuroSTAT Project Receives FDA Fast Track DesignationLSE:0QDUAbliva Ab
07/04/20198:46AMPR Newswire (US)NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical StudyLSE:0QDUAbliva Ab
07/04/20198:45AMPR Newswire (US)NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical StudyLSE:0QDUAbliva Ab
05/21/20192:45AMPR Newswire (US)NeuroVive Pharmaceutical AB Interim Report January - March 2019LSE:0QDUAbliva Ab
05/10/20192:48AMPR Newswire (US)NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDALSE:0QDUAbliva Ab
05/10/20192:46AMPR Newswire (US)NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDALSE:0QDUAbliva Ab
03/25/20195:48AMPR Newswire (US)NeuroVive Pharmaceutical AB Publishes 2018 Annual ReportLSE:0QDUAbliva Ab
03/25/20195:43AMPR Newswire (US)NeuroVive Pharmaceutical AB Publishes 2018 Annual ReportLSE:0QDUAbliva Ab
03/07/20193:07AMPR Newswire (US)NeuroVive Receives SEK 28.2 Million in a Directed New Share IssueLSE:0QDUAbliva Ab
02/21/20192:52AMPR Newswire (US)NeuroVive Enters Commercial Partnership With Oroboros Instruments on Mitochondrial Medicine Research CompoundsLSE:0QDUAbliva Ab
11/15/20186:25AMPR Newswire (US)NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial DisordersLSE:0QDUAbliva Ab
11/15/20186:21AMPR Newswire (US)NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial DisordersLSE:0QDUAbliva Ab
10/31/20184:07AMPR Newswire (US)NeuroVive Today Announces That the Subscription Period for Warrants of Series 2018:1 Will Begin on Thursday, November 1LSE:0QDUAbliva Ab
10/04/20182:50AMPR Newswire (US)NeuroVive Reports First NeuroSTAT Clinical Efficacy Signal in TBILSE:0QDUAbliva Ab
10/04/20182:45AMPR Newswire (US)NeuroVive Reports First NeuroSTAT Clinical Efficacy Signal in TBILSE:0QDUAbliva Ab
12/11/20175:41AMPR Newswire (US)NeuroVive Reports Promising Progress in its Clinical Project for Genetic Mitochondrial Diseases, KL1333LSE:0QDUAbliva Ab
12/11/20175:38AMPR Newswire (US)NeuroVive Reports Promising Progress in its Clinical Project for Genetic Mitochondrial Diseases, KL1333LSE:0QDUAbliva Ab
 Showing the most relevant articles for your search:LSE:0QDU

Your Recent History

BIT
SDF
K and S
NYSE
JCD
Cendant Upper Decs
BIT
UC8AKJ
Unicredit Bank
BIT
F34622
Vontobel Financial Produ...
COIN
PPDUSD
COIN
SBTTTTTBTC
SUNBLOCKTERMINAL
BOV
CASH3
Meliuz S.A ON
EU
E973T
E973T
NYSE
IMP
EU
A904T
A904T
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved